Fasikl’s Felix NeuroAI Wristband Outperforms Sham in Essential Tremor Study
Fasikl’s NeuroAI™ Wristband Demonstrates Breakthrough Results in Pivotal TRANQUIL Study for Essential Tremor Fasikl, a pioneering neuro-AI company at the forefront of integrating bioelectronic medicine with artificial intelligence, today announced that its landmark TRANQUIL study met its primary endpoint. The…
Teladoc Health Launches Advanced Cardiometabolic Health Program
Teladoc Health Unveils Next-Generation Cardiometabolic Health Program to Combat Chronic Disease Teladoc Health (NYSE: TDOC), a global leader in virtual healthcare, has announced the launch of its next-generation Cardiometabolic Health Program aimed at improving overall population health and preventing the…
QIAGEN Surpasses Q1 2025 Outlook, Raises Full-Year EPS Forecast
QIAGEN Surpasses Q1 2025 Outlook, Raises Full-Year EPS Forecast QIAGEN NV (NYSE: QGEN; Frankfurt Prime Standard: QIA) has announced strong preliminary results for the first quarter of 2025, surpassing both its previous guidance for net sales and adjusted earnings per…
Sentynl Therapeutics Unveils First Clinical Evidence Supporting NULIBRY® for Molybdenum Cofactor Deficiency Type A
Sentynl Therapeutics Unveils First Clinical Evidence Supporting NULIBRY® for Molybdenum Cofactor Deficiency Type A Sentynl Therapeutics, Inc., a U.S.-based biopharmaceutical company wholly owned by Zydus Lifesciences, Ltd., has announced the publication of groundbreaking clinical data regarding NULIBRY® (fosdenopterin) in the…
Study Finds K Health’s AI Recommendations Match Doctors’ in Accuracy
Study Finds K Health’s AI Recommendations Match Doctors’ in Accuracy K Health, a leading AI-driven primary care platform, recently revealed exciting results from a novel study demonstrating that its AI-powered Physician Mode closely matched doctors’ clinical decisions in two-thirds of…
U of A Study: Openwater’s Open-LIFU 2.0 Reduces Depression Symptoms in Under 2 Hours
U of A Study: Openwater’s Open-LIFU 2.0 Reduces Depression Symptoms in Under 2 Hours Openwater, a leader in open-source medical technology, has announced breakthrough results from a study conducted by the University of Arizona, published in Frontiers in Psychiatry. The…
Viz.ai Wins 2025 Edison Award™ for Machine Learning Innovation for Third Year
Viz.ai Wins 2025 Edison Award™ for Machine Learning Innovation for Third Year Viz.ai, a leader in artificial intelligence (AI)-powered disease detection and intelligent care coordination, has announced its recognition as an Award Winner in the 2025 Edison Awards, marking the…
UCI Health Enhances Web Experience with aha! Platform Acquisition
UCI Health Enhances Web Experience with aha! Platform Acquisition Abundant Health Acquisition (aha!) is proud to announce the launch of UCI Health’s newly redesigned website, built on aha!’s Health Experience Platform (HXP). This major update enhances the user experience for…
ABEC Unveils Single-Use Bioreactor for Cell Therapy Manufacturing
ABEC Unveils Single-Use Bioreactor for Cell Therapy Manufacturing ABEC, a global leader in engineered solutions for biotechnology manufacturing, has introduced its Advanced Therapy Bioreactor (ATB™), a groundbreaking platform designed to advance the manufacturing of advanced therapy medicinal products (ATMPs). The…
ENHERTU® Approved in the EU for HER2-Low Metastatic Breast Cancer
ENHERTU® Approved in the EU for HER2-Low Metastatic Breast Cancer Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) announced the approval of ENHERTU® (trastuzumab deruxtecan) in the European Union (EU) as a monotherapy for the treatment of adult patients with…
Universal Health Services Releases 2024 Annual Report
Universal Health Services Releases 2024 Annual Report Universal Health Services (NYSE: UHS), one of the nation’s largest and most respected providers of hospital and healthcare services, has unveiled its 2024 Annual Report, underscoring the company’s significant achievements and commitment to…
GeneDx Expands Exome and Genome Testing to Include Inborn Errors of Immunity
GeneDx Expands Exome and Genome Testing to Include Inborn Errors of Immunity GeneDx (Nasdaq: WGS), a leader in genomic diagnostics, has announced the expansion of its commercial focus to include Inborn Errors of Immunity (IEI). IEIs are a group of…